Pulmatrix Inc Total Liabilities
Pulmatrix Inc total liabilities. Based on the latest financial reports, Pulmatrix Inc (PULM) has total liabilities worth $905.00K USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Pulmatrix Inc's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Pulmatrix Inc (2012–2025)
Total liabilities of Pulmatrix Inc from 2012 to 2025. This chart illustrates how Pulmatrix Inc's total liabilities have evolved over time, based on quarterly financial data.
Pulmatrix Inc Competitors by Total Liabilities
The table below lists competitors of Pulmatrix Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Castelbajac Co. Ltd
KQ:308100
|
Korea | ₩70.93 Billion |
|
Above Food Ingredients Inc. Common Stock
NASDAQ:ABVE
|
USA | $227.56 Million |
|
INDUSTRIAL MINERALS LTD
F:9ED
|
Germany | €490.04K |
|
HYDROTOR SA
WAR:HDR
|
Poland | zł67.35 Million |
|
Xpon Technologies Group Ltd
AU:XPN
|
Australia | AU$16.05 Million |
|
Iceni Gold Ltd
AU:ICL
|
Australia | AU$1.11 Million |
|
Invesco Bond Income Plus Limited
LSE:BIPS
|
UK | GBX56.77 Million |
|
Stenocare AS
CO:STENO
|
Denmark | Dkr3.73 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down Pulmatrix Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Pulmatrix Inc balance sheet assets.
Liquidity & Leverage Metrics
Pulmatrix Inc Total Liabilities Ratios Explained
Pulmatrix Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pulmatrix Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pulmatrix Inc (2012–2025)
The table below shows the annual total liabilities of Pulmatrix Inc from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $329.00K | -66.97% |
| 2024-12-31 | $996.00K | -93.76% |
| 2023-12-31 | $15.96 Million | +62.16% |
| 2022-12-31 | $9.84 Million | -13.41% |
| 2021-12-31 | $11.37 Million | -24.36% |
| 2020-12-31 | $15.03 Million | -40.07% |
| 2019-12-31 | $25.08 Million | +771.10% |
| 2018-12-31 | $2.88 Million | -50.71% |
| 2017-12-31 | $5.84 Million | -26.08% |
| 2016-12-31 | $7.90 Million | -35.58% |
| 2015-12-31 | $12.27 Million | +1195.35% |
| 2014-12-31 | $947.00K | 0.00% |
| 2013-12-31 | $947.00K | +837.62% |
| 2012-12-31 | $101.00K | -- |
About Pulmatrix Inc
Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.… Read more